

69 NO:7 shown in Figure 15A; SEQ ID NO:15 shown in Figure 15B) --; after
"Y0313-2", insert -- (SEQ ID NO:8 shown in Figure 15A; SEQ ID NO:16
B10 shown in Figure 15B) --.

On page 13, line 13, delete "WO 98/54331" and insert -- WO
98/45331 --.

On page 13, line 14, delete "WO 98/54332" and insert -- WO
98/45332 --.

IN THE CLAIMS:

Please cancel claims 7 and 23 without prejudice.

B10 C3 1. (Amended) A method of treating a mammal having edema comprising
administering to said mammal an effective amount of hVEGF antagonist,
wherein said antagonist comprises an anti-VEGF antibody.

B12 22. (Amended) A method of treating a mammal having cerebral edema
comprising administering to said mammal an effective amount of hVEGF
antagonist, wherein said antagonist comprises an anti-VEGF antibody.

REMARKS

Claims 1-29 are pending and are the subject of the office action.
As shown in the above amendment, the specification has been amended to
correct several inadvertent typographical errors relating to certain
art reference citations. The specification has also been amended to
recite various SEQ ID NO:s, as discussed below. The claims have also
been amended in connection with the restriction requirement, as
discussed below.

In the office action, the Examiner set forth a restriction
requirement pursuant to 35 USC Section 121. Specifically, the
Examiner set forth a restriction of six (6) groups of claims, Groups I
- VI. Applicants hereby elect to prosecute in the instant application
claims drawn to Group I identified by the Examiner (e.g., claims
directed to methods of treating edema using antibodies). With respect
to the election of species requirement set forth by the Examiner,
Applicants would appreciate clarification of this imposed requirement
for the record. Applicants do hereby elect to prosecute in the
instant application claims drawn to monoclonal antibodies. It is